Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing

References

• Grilo AL, Mantalaris A. The increasingly human and profitable monoclonal antibody market. Trends Biotechnol. 2019;37:1–11. doi:https://doi.org/10.1016/j.tibtech.2018.05.014.
   PubMedGoogle Scholar
• IAVI and the Wellcome Trust, Expanding access to monoclonal antibody-based products: a global call to action. 2020.
   Google Scholar
• Hadley S. Biologicals for global health: the case for lower cost drugs. ECI Conference on Integrated Continuous Biomanufacturing; 2013; Castelldefels, Spain.
   Google Scholar
• Ecker DM, Seymour P. Supply and demand trends: mammalian biomanufacturing industry overview. Bioprocess Int. 2020;18:10–14.
   Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2021. mAbs. 2021;13:1860476. doi:https://doi.org/10.1080/19420862.2020.1860476.
   PubMed Web of Science ®Google Scholar
• Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46–61. doi:https://doi.org/10.1038/nri.2017.106.
   PubMed Web of Science ®Google Scholar
• Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Children. 1986;140:543–46. doi:https://doi.org/10.1001/archpedi.1986.02140200053026.
   PubMedGoogle Scholar
• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98. doi:https://doi.org/10.1056/NEJMoa0804877.
   PubMed Web of Science ®Google Scholar
• Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31:5–9. doi:https://doi.org/10.1097/INF.0b013e31822e68e6.
   PubMed Web of Science ®Google Scholar
• Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi:https://doi.org/10.1016/S0140-6736(17)30938-8.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–128. doi:https://doi.org/10.1016/S0140-6736(12)61728-0.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets. 2012;12:98–102. doi:https://doi.org/10.2174/187152612800100116.
   PubMedGoogle Scholar
• Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis. 2012;206(1):56–62. doi:https://doi.org/10.1093/infdis/jis309.
   PubMed Web of Science ®Google Scholar
• Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ. 2012;15:987–96. doi:https://doi.org/10.3111/13696998.2012.690013.
   PubMedGoogle Scholar
• Head BM, Rubinstein E, Meyers AF. Alternative pre-approved and novel therapies for the treatment of anthrax. BMC Infect Dis. 2016;16:621. doi:https://doi.org/10.1186/s12879-016-1951-y.
   PubMedGoogle Scholar
• Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7:526–36. doi:https://doi.org/10.1038/nrmicro2164.
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–208. doi:https://doi.org/10.1056/NEJMoa1306801.
   PubMed Web of Science ®Google Scholar
• Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. 2008;359:1932–40. doi:https://doi.org/10.1056/NEJMra0707500.
   PubMed Web of Science ®Google Scholar
• Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe. 2015;34:59–73. doi:https://doi.org/10.1016/j.anaerobe.2015.04.012.
   PubMed Web of Science ®Google Scholar
• Mounsey A, Lacy Smith K, Reddy VC, Nickolich S. Clostridioides difficile infection: update on management. Am Fam Physician. 2020;101:168–75.
   PubMed Web of Science ®Google Scholar
• Kufel WD. Antibody-based strategies in HIV therapy. Int J Antimicrob Agents. 2020;56:106186. doi:https://doi.org/10.1016/j.ijantimicag.2020.106186.
   PubMedGoogle Scholar
• Rana AI, Castillo-Mancilla JR, Tashima KT, Landovitz RL. Advances in long-acting agents for the treatment of HIV infection. Drugs. 2020;80:535–45. doi:https://doi.org/10.1007/s40265-020-01284-1.
   PubMed Web of Science ®Google Scholar
• Millham L, Scott J, Sax P, Shebl FM, Reddy KP, Losina E, Walensky RP, Freedberg KA. Clinical and economic impact of ibalizumab for patients with multidrug-resistant HIV in the United States. 10th IAS Conference on HIV Science; 2019; Mexico City.
   Google Scholar
• Sparrow E, Torvaldsen S, Newall AT, Wood JG, Sheikh M, Kieny MP, Abela-Ridder B. Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline. Vaccine. 2019;37(Suppl 1):A132–A139. doi:https://doi.org/10.1016/j.vaccine.2018.11.004.
   PubMed Web of Science ®Google Scholar
• Jacob ST, Crozier I, Fischer WA, Hewlett A, Kraft CS, de La Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, et al. Ebola virus disease. Nat Rev Dis Primers. 2020;6:13.
   PubMed Web of Science ®Google Scholar
• CDC. 2020 https://www.cdc.gov/vhf/ebola/history/distribution-map.html.
   Google Scholar
• Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303. doi:https://doi.org/10.1056/NEJMoa1910993.
   PubMed Web of Science ®Google Scholar
• Prevail II Writing Group, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375:1448–56. doi:https://doi.org/10.1056/NEJMoa1604330.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2035002.
   Google Scholar
• Meissner HC Disarming the respiratory syncytial virus. N Engl J Med. 2020;383:487–88. doi:https://doi.org/10.1056/NEJMe2021648.
   PubMedGoogle Scholar
• Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–25. doi:https://doi.org/10.1056/NEJMoa1913556.
   PubMed Web of Science ®Google Scholar
• Walsh EE. Respiratory syncytial virus infection: an illness for all ages. Clin Chest Med. 2017;38:29–36. doi:https://doi.org/10.1016/j.ccm.2016.11.010.
   PubMed Web of Science ®Google Scholar
• Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ. PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection. HIV Clin Trials. 2018;19:85–93. doi:https://doi.org/10.1080/15284336.2018.1452842.
   PubMed Web of Science ®Google Scholar
• Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, Dubovsky F, Griffin MP. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018;37(9):886–92. doi:https://doi.org/10.1097/INF.0000000000001916.
   PubMed Web of Science ®Google Scholar
• Gaudinski MR, Coates EE, Houser KV, Chen GL, Yamshchikov G, Saunders JG, Holman LA, Gordon I, Plummer S, Hendel CS, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018;15(1):e1002493. doi:https://doi.org/10.1371/journal.pmed.1002493.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Khan AA, Esser MT, Jensen K, Takas T, Kankam MK, Villafana T, Dubovsky F. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017;61(3). doi:https://doi.org/10.1128/AAC.01714-16.
   Web of Science ®Google Scholar
• Yu XQ, Robbie GJ, Wu Y, Esser MT, Jensen K, Schwartz HI, Bellamy T, Hernandez-Illas M, Jafri HS. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother. 2017;61. doi:https://doi.org/10.1128/AAC.01020-16.
   Google Scholar
• Anderson DJ, Politch JA, Zeitlin L, Hiatt A, Kadasia K, Mayer KH, Ruprecht RM, Villinger F, Whaley KJ. Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. AIDS. 2017;31:1505–17. doi:https://doi.org/10.1097/QAD.0000000000001521.
   PubMed Web of Science ®Google Scholar
• Sok D, Burton DR. Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol. 2018;19:1179–88. doi:https://doi.org/10.1038/s41590-018-0235-7.
   PubMed Web of Science ®Google Scholar
• Corey L. VRC01 antibody prevention of HIV. HIVR4P; 2021. https://programme.hivr4p.org/Search/Search?search=corey
   Google Scholar
• Ramirez Valdez KP, Kuwata T, Maruta Y, Tanaka K, Alam M, Yoshimura K, Matsushita S. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology. 2015;475:187–203. doi:https://doi.org/10.1016/j.virol.2014.11.011.
   PubMedGoogle Scholar
• Politch JA, Cu-Uvin S, Moench TR, Tashima KT, Marathe JG, Guthrie KM, Cabral H, Nyhuis T, Brennan M, Zeitlin L, et al. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): a Phase I randomized trial. PLoS Med. 2021;18(2):e1003495. doi:https://doi.org/10.1371/journal.pmed.1003495.
   PubMed Web of Science ®Google Scholar
• Zhao C, Gunawardana M, Villinger F, Baum MM, Remedios-Chan M, Moench TR, Zeitlin L, Whaley KJ, Bohorov O, Smith TJ, et al. Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model. Antimicrob Agents Chemother. 2017;61(7). doi:https://doi.org/10.1128/AAC.02465-16.
   Google Scholar
• Anderson DJ, Politch JA, Cone RA, Zeitlin L, Lai SK, Santangelo PJ, Moench TR, Whaley KJ. Engineering monoclonal antibody-based contraception and multipurpose prevention technologiesdagger. Biol Reprod. 2020;103:275–85. doi:https://doi.org/10.1093/biolre/ioaa096.
   PubMed Web of Science ®Google Scholar
• Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. Jama. 2020;324(2):131–32. doi:https://doi.org/10.1001/jama.2020.10245.
   PubMed Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2029849.
   Web of Science ®Google Scholar
• Activ-Tico Ly-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2020. doi:https://doi.org/10.1056/NEJMoa2033130.
   Google Scholar
• Regeneron. REGN-COV2 independent data monitoring committee recommends holding enrollment in hospitalized patients with high oxygen requirements and continuing enrollment in patients with low or no oxygen requirements. 2020.
   Google Scholar
• Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021;26. doi:https://doi.org/10.2807/1560-7917.ES.2020.26.1.2002106.
   Google Scholar
• Harris R. Doctors encouraged by antibody treatments for COVID-19. NPR; 2021. https://www.wnyc.org/story/doctors-encouraged-by-antibody-treatments-for-covid-19
   Google Scholar
• Isha Sharma MW, Kroetsch A, Sullivan H, McClellan M. COVID-19 manufacturing for monoclonal antibodies. Duke Margolis Center for Health Policy; updated August 2020.
   Google Scholar
• Troeger CE, Blacker BF, Khalil IA, Zimsen SRM, Albertson SB, Abate D, Abdela J, Adhikari TB, Aghayan SA, Agrawal S. GBDI collaborators, mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the global burden of disease study 2017. Lancet Respir Med. 2019;7:69–89. doi:https://doi.org/10.1016/S2213-2600(18)30496-X.
   PubMed Web of Science ®Google Scholar
• Rudraraju R, Subbarao K. Passive immunization with influenza haemagglutinin specific monoclonal antibodies. Hum Vaccin Immunother. 2018;14:2728–36. doi:https://doi.org/10.1080/21645515.2018.1489947.
   PubMed Web of Science ®Google Scholar
• Sparrow E, Friede M, Sheikh M, Torvaldsen S, Newall AT. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine. 2016;34:5442–48. doi:https://doi.org/10.1016/j.vaccine.2016.08.057.
   PubMed Web of Science ®Google Scholar
• Behzadi MA, Leyva-Grado VH. Overview of current therapeutics and novel candidates against influenza, respiratory syncytial virus, and middle east respiratory syndrome coronavirus infections. Front Microbiol. 2019;10:1327. doi:https://doi.org/10.3389/fmicb.2019.01327.
   PubMed Web of Science ®Google Scholar
• WHO. World malaria report 2019. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK, Murphy S, Schön A, Freire E, Francica JR, et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med. 2018;24:408–16. doi:https://doi.org/10.1038/nm.4512.
   PubMed Web of Science ®Google Scholar
• Kolata G. Alzheimer’s drug shows promise in small trial. New York Times. 2021.
   Google Scholar
• Walther J, Godawat R, Hwang C, Abe Y, Sinclair A, Konstantinov K. The business impact of an integrated continuous biomanufacturing platform for recombinant protein production. J Biotechnol. 2015;213:3–12. doi:https://doi.org/10.1016/j.jbiotec.2015.05.010.
   PubMed Web of Science ®Google Scholar
• Gupta P, Kateja N, Mishra S, Kaur H, Rathore AS. Economic assessment of continuous processing for manufacturing of biotherapeutics. Biotechnol Prog. 2020:e3108. doi:https://doi.org/10.1002/btpr.3108.
   Google Scholar
• Giritch A, Marillonnet S, Engler C, Van Eldik G, Botterman J, Klimyuk V, Gleba Y. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA. 2006;103(40):14701–06. doi:https://doi.org/10.1073/pnas.0606631103.
   PubMed Web of Science ®Google Scholar
• Pogue GP, Vojdani F, Palmer KE, Hiatt E, Hume S, Phelps J, Long L, Bohorova N, Kim D, Pauly M, et al. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol J. 2010;8(5):638–54. doi:https://doi.org/10.1111/j.1467-7652.2009.00495.x.
   PubMed Web of Science ®Google Scholar
• Castilho A, Steinkellner H. Glyco-engineering in plants to produce human-like N-glycan structures. Biotechnol J. 2012;7:1088–98. doi:https://doi.org/10.1002/biot.201200032.
   PubMedGoogle Scholar
• Strasser R, Stadlmann J, Schähs M, Stiegler G, Quendler H, Mach L, Glössl J, Weterings K, Pabst M, Steinkellner H, et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J. 2008;6:392–402. doi:https://doi.org/10.1111/j.1467-7652.2008.00330.x.
   PubMed Web of Science ®Google Scholar
• Van Eldik G, Weterings K. Nicotiana benthamiana plants deficient in xylosyltransferase activity. ed USPTO (Icon Genetics GmbH); 2015.
   Google Scholar
• Van Eldik G, Weterings K. Nicotiana benthamiana plants deficient in fucosyltransferase activity. ed USPTO (Icon Genetics GmbH); 2019.
   Google Scholar
• Bendandi M, Marillonnet S, Kandzia R, Thieme F, Nickstadt A, Herz S, Fröde R, Inogés S, Lòpez-dìaz De Cerio A, Soria E, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin’s lymphoma. Ann Oncol. 2010;21:2420–27. doi:https://doi.org/10.1093/annonc/mdq256.
   PubMed Web of Science ®Google Scholar
• Nandi S, Kwong AT, Holtz BR, Erwin RL, Marcel S, McDonald KA. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production. mAbs. 2016;8(8):1456–66. doi:https://doi.org/10.1080/19420862.2016.1227901.
   PubMed Web of Science ®Google Scholar
• Jiang H, Horwitz AA, Wright C, Tai A, Znameroski EA, Tsegaye Y, Warbington H, Bower BS, Alves C, Co C, et al. Challenging the workhorse: comparative analysis of eukaryotic microorganisms for expressing monoclonal antibodies. Biotechnol Bioeng. 2019;116(6):1449–62. doi:https://doi.org/10.1002/bit.26951.
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, Bobrowicz P, Stadheim TA, Li H, Choi B-K, et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science. 2006;313:1441–43. doi:https://doi.org/10.1126/science.1130256.
   PubMed Web of Science ®Google Scholar
• Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, Bobrowicz P, Choi B-K, Cook WJ, Cukan M, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol. 2006;24(2):210–15. doi:https://doi.org/10.1038/nbt1178.
   PubMed Web of Science ®Google Scholar
• Ye J, Ly J, Watts K, Hsu A, Walker A, McLaughlin K, Berdichevsky M, Prinz B, Sean Kersey D, d’Anjou M, et al. Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production. Biotechnol Prog. 2011;27(6):1744–50. doi:https://doi.org/10.1002/btpr.695.
   PubMedGoogle Scholar
• Estell D. Adapting industry practices for the rapid, large-scale manufacture of pharmaceutical proteins. Bridge. 2006;36:39–44.
   Google Scholar
• Huuskonen A. Development of the filamentous fungus Myceliophthora thermophila C1 into a next-generation therapeutic protein production system. ECFG15; 2020; Rome, Italy.
   Google Scholar
• WHO. WHO antifungal expert group on identifying priority fungal pathogens: first meeting report. Geneva, Switzerland: World Health Organization; 2020.
   Google Scholar
• Federal task force on combating antibiotic-resistant bacteria. 2020. National action plan for combating antibiotic-resistant bacteria. Washington, D.C: U.S. Department of Health and Human Services.
   Google Scholar
• Zeitlin L, Cone RA, Whaley KJ. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. Emerg Infect Dis. 1999;5:54–64. doi:https://doi.org/10.3201/eid0501.990107.
   PubMed Web of Science ®Google Scholar
• Schiller JL, Fogle MM, Bussey O, Kissner WJ, Hill DB, Lai SK. Antibody-mediated trapping in biological hydrogels is governed by sugar-sugar hydrogen bonds. Acta Biomater. 2020;107:91–101. doi:https://doi.org/10.1016/j.actbio.2020.03.002.
   PubMed Web of Science ®Google Scholar
• Schroeder HA, Newby J, Schaefer A, Subramani B, Tubbs A, Gregory Forest M, Miao E, Lai SK. LPS-binding IgG arrests actively motile Salmonella Typhimurium in gastrointestinal mucus. Mucosal Immunol. 2020;13(5):814–23. doi:https://doi.org/10.1038/s41385-020-0267-9.
   PubMed Web of Science ®Google Scholar
• Yang B, Schaefer A, Wang -Y-Y, McCallen J, Lee P, Newby JM, Arora H, Kumar PA, Zeitlin L, Whaley KJ, et al. ZMapp reinforces the airway mucosal barrier against Ebola virus. J Infect Dis. 2018;218(6):901–10. doi:https://doi.org/10.1093/infdis/jiy230.
   PubMedGoogle Scholar
• Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, Hein MB, Lehner T. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med. 1998;4(5):601–06. doi:https://doi.org/10.1038/nm0598-601.
   PubMed Web of Science ®Google Scholar
• Booth V, Ashley FP, Lehner T. Passive immunization with monoclonal antibodies against porphyromonas gingivalis in patients with periodontitis. Infect Immun. 1996;64:422–27. doi:https://doi.org/10.1128/IAI.64.2.422-427.1996.
   PubMed Web of Science ®Google Scholar
• Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine. 2021;39:2190–200. doi:https://doi.org/10.1016/j.vaccine.2021.03.038.
   PubMed Web of Science ®Google Scholar
• Van Hoecke L, Roose K. How mRNA therapeutics are entering the monoclonal antibody field. J Transl Med. 2019;17:54. doi:https://doi.org/10.1186/s12967-019-1804-8.
   PubMed Web of Science ®Google Scholar
• Tiwari PM, Vanover D, Lindsay KE, Bawage SS, Kirschman JL, Bhosle S, Lifland AW, Zurla C, Santangelo PJ. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat Commun. 2018;9:3999. doi:https://doi.org/10.1038/s41467-018-06508-3.
   PubMed Web of Science ®Google Scholar
• Lindsay KE, Vanover D, Thoresen M, King H, Xiao P, Badial P, Araínga M, Park SB, Tiwari PM, Peck HE, et al. Aerosol delivery of synthetic mRNA to vaginal mucosa leads to durable expression of broadly neutralizing antibodies against HIV. Mol Ther. 2020;28(3):805–19. doi:https://doi.org/10.1016/j.ymthe.2020.01.002.
   PubMedGoogle Scholar
• Moderna. Moderna announces positive Phase 1 results for the first systemic messenger RNA therapeutic encoding a secreted protein (mRNA–1944). Press release. 2019. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-phase-1-results-first-systemic
   Google Scholar